Nocloprost 

Nocloprost, a prostaglandin E2 (PGE2) analog, is an orally active EP1- and EP3-receptor agonist. Nocloprost inhibits evoked [³H]ACh release. Nocloprost has gastroprotective and ulcer-healing properties. Nocloprost accelerates the healing of chronic gastric ulcerations and enhances mucosal growth in rats^[1][2].

Nocloprost (intragastrically; 0.01-10 μg/kg) 30 min before 100% ethanol, acidified Aspirin (HY-14654), acidified Taurocholate (HY-N0545), water immersion, or restraint stress dose dependently prevents the formation of gastric lesions in rats^[1].
Nocloprost (i.g.; 0.01-100 μg/kg) failes to affect gastric acid secretion or intestinal secretion (enteropooling) but preventes the increased gastroduodenal alkaline secretion^[1].
Nocloprost (s.c.) shows protective activity against ethanol damage but is ineffective when applied intraduodenally^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

400.98

C₂₂H₃₇ClO₄

79360-43-3

CCCCC(C)(C)[C@H](O)/C=C/[C@@H]1[C@H]([C@H](Cl)C[C@H]1O)C/C=C\CCCC(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. S J Konturek, et al. Nocloprost, a unique prostaglandin E2 analog with local gastroprotective and ulcer-healing activity. Eur J Pharmacol. 1991 Apr 3;195(3):347-57.  [Content Brief]

  [2]. T Reinheimer, et al. Prostanoid receptors of the EP3 subtype mediate inhibition of evoked [3H]acetylcholine release from isolated human bronchi. Br J Pharmacol. 1998 Sep;125(2):271-6.  [Content Brief]